Al-Adra David P, Anderson Colin C
Department of Surgery, Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada.
Chimerism. 2013 Jan-Mar;4(1):23-5. doi: 10.4161/chim.23350. Epub 2013 Jan 1.
Mixed chimerism is a promising approach toward generating donor-specific immunological tolerance. However, chimerism induction can be toxic; therefore, there is an effort to develop non-myeloablative, minimal intensity protocols that can generate chimerism without the toxic side effects. Recently, with the goal of creating a minimalistic chimerism induction protocol in the tolerance resistant non-obese diabetic (NOD) mouse model, we identified pre-existing T cells as cells that resist fully allogeneic chimerism. With monoclonals targeting NOD T cells, we showed that long-term chimerism and tolerance toward donor islets could be established. However, this promising new protocol relied on the administration of a single dose of anti-CD40 ligand, which is not clinically applicable. In refining protocols to move even closer to clinical utility, we report here initial success at generating fully allogeneic mixed chimerism in NOD mice by adding cyclophosphamide to the conditioning regimen in place of anti-CD40 ligand antibodies.
混合嵌合体是诱导供体特异性免疫耐受的一种很有前景的方法。然而,嵌合体诱导可能具有毒性;因此,人们致力于开发非清髓性、低强度方案,该方案能够在不产生毒副作用的情况下诱导嵌合体形成。最近,为了在耐受性良好的非肥胖糖尿病(NOD)小鼠模型中创建一种极简嵌合体诱导方案,我们确定了预先存在的T细胞是抵抗完全异基因嵌合体的细胞。通过针对NOD T细胞的单克隆抗体,我们证明可以建立长期嵌合体以及对供体胰岛的耐受性。然而,这种有前景的新方案依赖于单次注射抗CD40配体,这在临床上并不适用。在改进方案以使其更接近临床应用时,我们在此报告,通过在预处理方案中添加环磷酰胺替代抗CD40配体抗体,在NOD小鼠中成功诱导出完全异基因混合嵌合体。